SCIENTIFIC PROGRAMME
SESSION I
THE GENOMIC AND
EPIGENOMIC LANDSCAPE
OF CLL AND CLINICAL
CONSEQUENCES
SESSION II
THE ROLE OF BCR
ACTIVATION AND
SIGNALLING FOR CLL
SESSION III
THERAPEUTIC OPTIONS
FOR CLL
SESSION IV
LONG TERM FOLLOW
UP OF CLINICAL TRIALS
VERSUS REAL WORLD
DATA (OUTSIDE CLINICAL
TRIALS DATA-OCT)
SESSION V
THE INCREASING ROLE
OF THE LEUKAEMIC
MICROENVIRONMENT
SESSION VI
THERAPEUTIC OPTIONS 2 :
THE USE OF CELLULAR
AND NON-CELLULAR
IMMUNOTHERAPIES IN
CLL
SESSION VII
EFFICACY THROUGH
SAFETY
SESSION VIII
CLONAL HETEROGENEITY,
CLONAL EVOLUTION AND
MECHANISMS OF DRUG
RESISTANCE
SESSION IX
CONTRASTING
THERAPEUTIC CONCEPTS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
FACULTY DISCLOSURES
References
1. Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable
disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results
of the German CLL Study Group CLL3X trial. Blood. 2010;116(14):2438-47.
2. Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and Richter
transformation or with relapsed CLL. Blood. 2017;129(26):3419-27.
3. Vardi A, Agathangelidis A, Stalika E, et al. Antigen Selection Shapes the T-cell Repertoire in
Chronic Lymphocytic Leukemia. Clin Cancer Res. 2016;22(1):167-74.
4. Yin Q, Sivina M, Robins H, et al. Ibrutinib Therapy Increases T Cell Repertoire Diversity in
Patients with Chronic Lymphocytic Leukemia. J Immunol. 2017;198(4):1740-7.
5. Rezvany MR, Jeddi-Tehrani M, Osterborg A, Kimby E, Wigzell H, Mellstedt H. Oligoclonal TCRBV
gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen
within the CD4 T-cell subset. Blood. 1999;94(3):1063-9.
6. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce
sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med.
2015;7(303):303ra139.
7. Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19
chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med.
2018;24(5):563-71.
8. Mueller KT, Maude SL, Porter DL, et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell
acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 2017;130(21):2317-
25.
9. Hoffmann JM, Schubert ML, Wang L, et al. Differences in Expansion Potential of Naive Chimeric
Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia
Patients. Front Immunol. 2017;8:1956.
10. Fraietta JA, Beckwith KA, Patel PR, et al. Ibrutinib enhances chimeric antigen receptor T-cell
engraftment and efficacy in leukemia. Blood. 2016;127(9):1117-27.
11. van Bruggen JAC, Martens AWJ, Fraietta JA, et al. Chronic lymphocytic leukemia cells impair
mitochondrial fitness in CD8(+) T cells and impede CAR T-cell efficacy. Blood. 2019;134(1):44-
58.
12. Robinson HR, Qi J, Cook EM, et al. A CD19/CD3 bispecific antibody for effective immunotherapy
of chronic lymphocytic leukemia in the ibrutinib era. Blood. 2018;132(5):521-32.
13. Coscia M, Vitale C, Peola S, et al. Dysfunctional Vgamma9Vdelta2 T cells are negative
prognosticators and markers of dysregulated mevalonate pathway activity in chronic
lymphocytic leukemia cells. Blood. 2012;120(16):3271-9.
14. de Weerdt, I., Hofland, T., Lameris, R., Endstra, S., Jongejan, A., Moerland, P. D., de Bruin, R. C.
G., Remmerswaal, E. B. M., Ten Berge, I. J. M., Liu, N., van der Stelt, M., Faber, L. M., Levin, M.
D., Eldering, E., Tonino, S. H., de Gruijl, T. D., van der Vliet, H. J., and Kater, A. P. (2018)
Improving CLL Vgamma9Vdelta2-T-cell fitness for cellular therapy by ex vivo activation and
ibrutinib. Blood 132, 2260-2272
15. Hofland, T., Eldering, E., Kater, A. P., and Tonino, S. H. (2019) Engaging Cytotoxic T and NK Cells
for Immunotherapy in Chronic Lymphocytic Leukemia. Int J Mol Sci 20